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Introduction {#sec005}
============

Even if national and international guidelines consider both surgery and radiotherapy (RT) as treatments of choice for localized Prostate Cancer (PCA) \[[@pone.0224151.ref001]--[@pone.0224151.ref005]\], no randomized trials compared their efficacy in different risk groups, with the exception of Hamdy's study which examined 10-year outcomes of localized PCA treatments \[[@pone.0224151.ref006]\]. Active surveillance (AS), with the advantage of avoiding radical treatments side effects is also considered an option for patients affected by low/very low risk PCA \[[@pone.0224151.ref007]--[@pone.0224151.ref008]\].

Patients choosing to be treated may ultimately decide for themselves which treatment to undertake only after having received an adequate counselling and after having shared their decision with doctors \[[@pone.0224151.ref009]\]. Indeed, they may be confused by differing opinions experiencing the 'lost patient syndrome' that may get even worse if there is a lack of communication between different members of a multidisciplinary team (MDT) \[[@pone.0224151.ref010]\], even if managing patients with PCA in a MDT is considered desirable \[[@pone.0224151.ref011]\].

The study aims to assess the association of clinical and quality of life (QOL) characteristics with different patterns of care in a sample of PCA patients in Italy.

Materials and methods {#sec006}
=====================

"Pros-IT CNR" study {#sec007}
-------------------

The design of the Pros-IT CNR study has been described elsewhere \[[@pone.0224151.ref012]--[@pone.0224151.ref013]\]. Briefly, this on-going national, multicenter, observational, prospective, study was designed to monitor QoL in a sample of treatment-naïve Italian patients with PCA diagnosed between 2014 and 2015. Ninety-seven centers (urology, radiation and medical oncology facilities) located in Italy, enrolled 1705 consecutive patients: 949 in urology, 717 in radiation oncology and 39 in medical oncology departments. A baseline evaluation at the time PCA was diagnosed (and the patient was enrolled), and, 6, 12, 24, 36, 48 and 60 months later were/are foreseen for protocol \[[@pone.0224151.ref014]\]. Complete information about the chosen treatment was available at the 6 months follow up for the vast majority of patients enrolled (1493 patients at 6 months follow up, 97% of expected).

Ethics {#sec008}
------

The study protocol was approved by the Ethics Committee of the clinical coordinating center (Sant'Anna Hospital, Como, Italy; register number 45/2014) and by those of the other participating centers. The study was carried out in accordance with the principles of the declaration of Helsinki. All the participants signed an informed consent form.

Study population {#sec009}
----------------

In the Pros-IT CNR study, 1705 patients were enrolled. For the present analysis 6-month follow-up data were available for 1537 patients without distant metastasis (while 32 had distant metastasis at diagnosis, 4 died and 132 were lost to follow-up) ([Fig 1](#pone.0224151.g001){ref-type="fig"}).

![Patients enrolled in the Pros-IT CNR study from prostate cancer diagnosis to the 6 months follow-up.](pone.0224151.g001){#pone.0224151.g001}

Data collection {#sec010}
---------------

Demographics/anamnestic data (weight, height, smoking status), comorbidities evaluated using the Cumulative Illness Rating Scale (CIRS) \[[@pone.0224151.ref015]\], pharmacological treatments, initial diagnosis, tumor stage and QOL scores were evaluated at the baseline (time of diagnosis). Information on life status, treatments prescribed and QOL are/were collected during follow-up evaluations. Characteristics of institution where the prostate cancer was diagnosed (presence of Urology unit, Radiation Oncology Unit, Medical Oncology Unit and/or Prostate Cancer Unit) as well as physician who enrolled the patient in the study (urologist,radiation oncologist or medical oncologist) were also collected.

Outcome measures analyzed {#sec011}
-------------------------

Patients' QOL was assessed at diagnosis and then during each follow-up evaluation using the Italian version of the University of California Los Angeles-Prostate Cancer Index \[[@pone.0224151.ref016]\], which measures health-related QOL in PCA by investigating six domains: urinary function and bother (UF, UB), bowel function and bother (BF, BB), sexual function and bother (SF, SB). Responses were scored from 0 to 100, and higher score mirror better QOL.

Additionally, the Italian version of the Short-Form Health Survey (SF-12 Standard v1 scale) \[[@pone.0224151.ref017]\] was administered. SF-12 includes physical/mental component subscales (PCS and MCS, respectively) both ranging from 0 to 100, with higher scores indicating better self-perceived health states.

Statistical analysis {#sec012}
--------------------

Data were analyzed without imputation of missing values. Categorical variables were presented as numbers and percentages. Continuous variables were reported as means and standard deviations (SD) or medians and quartile 1 (Q1) and quartile 3 (Q3). Normal distributions for continuous variables were tested using the Shapiro-Wilk test.

The patients' features at diagnosis, as well as the characteristics of institution where the prostate cancer was diagnosed (presence of Urology, Radiation Oncology or Medical Oncology Unit and/or Prostate Cancer Unit) were compared according to the different treatments selected for PCA applying Fisher\'s exact test or Chi-squared test for categorical variables; the Wilcoxon rank-sum test was employed to analyze the continuous variables. Post-hoc analyses with Bonferroni adjustment for multiple comparison were applied.

Exploratory multiple correspondence analysis (MCA) was performed to evaluate the relationships among patients 'characteristics at diagnosis to identify specific profiles \[[@pone.0224151.ref018]--[@pone.0224151.ref019]\]. MCA permits viewing graphically the relationships among variables, by defining a map of cross-tabulations where rows and columns are represented as profiles in multidimensional space. In MCA, active variables were used to search for the factorial solution (inertia), and included age, education, marital status, smoking status, family history of PCA, presence of diabetes, comorbidities, T stage, Gleason Score (GS), PSA level and characteristics of institution where the prostate cancer was diagnosed (presence of Urology, Radiation Oncology, Medical Oncology Unit, Prostate Cancer Unit). PCA treatments prescribed during the 6 months following diagnosis were considered as supplementary variables. A p-value of less than 0.05 for a 2-sided test was considered statistical significant. All the analyses were performed using SAS 9.4 software. Full data were presented at the Uro-Oncological Study Group Meeting during the Italian Radiation Oncologist National Conference recently held in Rimini (27--29 September 2019).

Results {#sec013}
=======

Treatment was stratified as follows: surgery alone (37.6%); surgery and RT (2.4%); surgery plus RT plus Androgen Deprivation Therapy (ADT; 1.8%); surgery and ADT (3%); exclusive RT or RT plus ADT (22% and 15%, respectively), ADT alone (7%), AS (6%) and brachytherapy (BT) (1%) ([Fig 2](#pone.0224151.g002){ref-type="fig"}). Information on treatments carried out during the six-month period following diagnosis was unavailable for 26 patients. The treatment groups included in these descriptive analyses were: surgery alone, surgery combined with RT, surgery combined with RT and ADT, exclusive RT, RT combined with ADT, AS and ADT alone; a total sample size of 1412 patients was considered for the present study.

![Prostate cancer treatments reported at the follow-up at 6 months.](pone.0224151.g002){#pone.0224151.g002}

Treatment features {#sec014}
------------------

Overall, 690 patients without distant metastasis at diagnosis underwent surgery for PCA. Of these, 58.8% underwent a robot-assisted radical prostatectomy (RARP), 24.1% an open radical prostatectomy (ORP), 15.7% a laparoscopic prostatectomy and 0.4% a palliative transurethral resection of the prostate. Information on the surgical approach was unavailable for less than 1% of patients. Three hundred seventy-six patients (57.6%) underwent nerve-sparing surgery and 328 (47.5%) lymphadenectomy.

RT with external beams was delivered to 634 patients of whom 75% underwent Image-Guided Radiation Therapy (IGRT). A three-dimensional conformal radiotherapy (3D-CRT) technique was used in 200 patients (33.2%), Intensity-Modulated Radiation Therapy (IMRT) in 248 (41.2%), Volumetric Modulated Arc Therapy (VMAT) in 147 (24.4%) and Stereotactic body radiotherapy (SBRT) in 7 (1.2%). The volume treated included prostate alone in 142 patients (24.7%), prostate plus seminal vesicles in 340 patients (59.2%) and prostate, seminal vesicles and pelvic nodes in 92 (16%). Active Surveillance was adopted in 90 patients (5.9%), while 413 received ADT: LH-RH agonist (215; 56.1%) was the most frequently prescribed ADT. LH-RH antagonists were prescribed to 55 patients; peripheral antiandrogen drugs to 43 and total androgenic blockade to 70.

Correlations between patient's characteristics and therapeutic features {#sec015}
-----------------------------------------------------------------------

Patients' characteristics at diagnosis, stratified by treatments received until follow-up at 6 months are outlined in [S1 Table](#pone.0224151.s001){ref-type="supplementary-material"}. Patients undergoing surgery alone or combined with RT or with RT/ADT were the youngest, along with those candidates to AS, followed by patients on RT and those on ADT (p\<0.0001). The prevalence of diabetes at diagnosis was 28.4% among patients on ADT alone, 22.8% among those on RT combined with ADT, 17.5% among those on exclusive RT and was ≤ 10% among those on surgery alone or AS (p\<0.0001 across groups). Higher percentages of patients undergoing ADT alone, RT combined with ADT or exclusive RT had three or more moderate/severe comorbidities according to CIRS (22.2%, 19.7% and 18%, respectively), compared to patients on AS or surgery (14.6% and 10.7%, respectively). They also reported taking a higher median number of drugs taken (2, 3 and 2), compared to patients undergoing surgery alone or AS (1 and 1; p = 0.0013 and p\<0.0001, respectively). There were no significant differences in the groups in the obesity prevalence rates.

The median PSA value at diagnosis was 6.5 ng/mL (Q1 = 5, Q3 = 9.1) and 6.2 ng/mL (Q1 = 4.8, Q3 = 7.7) in the surgery alone and AS groups, respectively. These values were significantly lower than those in the RT alone (7.0 ng/mL, Q1 = 5.2, Q3 = 10) and ADT (10.2 ng/mL, Q1 = 7, Q3 = 21) groups. Ninety-three percent of patients in AS, 50.8% in surgery alone, 45.9% in RT alone, and 17.8% in ADT alone groups had a GS ≤ 6 at diagnosis (p\<0.0001).

Considering the physician who enrolled each patient, 94.8% of patients in the surgery alone group were enrolled by urologists, 4.8% by radiation oncologists and 0.4% by medical oncologists. Conversely, 89.9% of patients in the RT group were enrolled by radiation oncologists, 8.4% by urologists and 1.7% by medical oncologists. Patients in the RT combined with ADT group were enrolled by urologists in 47.3% of cases, by radiation oncologists in 44.6% of cases and by medical oncologists in 8.2% of cases.

As far as QOL at diagnosis was concerned, the patients in surgery alone or AS groups had better UF, BF, SF, SF12 PCS scores than the others (p\<0.05). As described in Porreca A et al.\[[@pone.0224151.ref013]\], features at diagnosis associated with lower SF12 PCS scores (i.e. worst physical component scores) were older age, obesity, the presence of three or more moderate/severe comorbidities, having a Gleason score at diagnosis of ≥8, living in Southern regions of Italy and being widowed or single. Patients' characteristics at diagnosis associated with lower SF12 MCS scores (i.e. worst mental component score) were younger age, the presence of three or more moderate/severe comorbidities and having a T-score at diagnosis higher than T1. The main characteristic associated with lower UCLA-PCI scores was older age; furthermore, lower sexual function scores were associated with the presence of diabetes, three or more moderate/severe comorbidities, a T-score at diagnosis higher than T1 or a Gleason score of \>8.

MCA analysis showed that inertia was decomposed along two principal dimensions ([Fig 3](#pone.0224151.g003){ref-type="fig"}). The first axis accounted for 53% of the inertia and the second for a further 15%, giving a cumulative inertia of 68%. Ten modalities contributed to almost 60% of the variance of the axis 1 (*dimension 1)*: on the right of the axis, the most important modalities were PSA ≥ 20 ng/mL at diagnosis, GS ≥ 8, T3 or T4 staging, being 75--79 at diagnosis, having diabetes and having been enrolled by a medical or a radiation oncologist or in an Institution with no presence of an Urology Unit; to the left side, the most important modalities were T1 staging, GS ≤ 6, and being under 65 years at diagnosis. Axis 1 grouped together the diagnosis severity (GS, T staging) with age and diabetes. Four modalities contributed to 60% of the variance of the axis 2 (*dimension 2)*: having 3 or more comorbidities at diagnosis, having being diagnosed in an Institution without Radiation or Medical Oncology Unit were towards the top of the axis, while the main contributors towards the bottom was having been diagnosed in an Institution with a Prostate Cancer Unit. Supplementary variables (in this case, the treatment strategy selected) did not contribute to determining the solution, but they were projected onto the axis to facilitate interpretation of the analytical solution. AS and surgery alone were close to one other on the third quadrant, together with a GS ≤ 6, T1 staging, having at most two comorbidities, no diabetes, being younger than 69 years at the time of diagnosis and having being diagnosed in an Institution with an urology unit. RT was plotted on the fourth quadrant, together with the presence of a Medical or a Radiation Oncology Unit. ADT alone and RT plus ADT were plotted on the first quadrant, near to ≥ 80 years at diagnosis, a GS ≥ 8, T3/T4, PSA ≥20 ng/ml and having been enrolled by a medical oncologist. Surgery combined with RT and ADT was plotted on the second quadrant, far enough from the other factors, but near to the lack of a Prostate Cancer Unit in the Institution that performed the initial diagnosis. We chose not to consider QOL-related factors as active variables, because they were self-reported and their inclusion in the analysis did not substantially increase the inertia explained by the first two dimensions (70% vs 68%).

![Multiple Correspondence Analysis of PCA patients' characteristics at diagnosis.](pone.0224151.g003){#pone.0224151.g003}

Discussion {#sec016}
==========

The Pros-IT CNR study is mainly devoted to analyze the impact of patients' and treatments related features on QOL, and future analyses will evaluate changes in QOL following different prostate cancer treatments. The present work aimed to analyze data collected, considering patients' clinical features at diagnosis, according to the treatment path. The study structure has been conceived to take a picture of the "real world scenario" of Italian PCA patients treated in different centers at time of diagnosis, allowing also to consider the clinical behavior of Italian urologists and oncologists when choosing treatment for individual patient. The current study uncovered that surgery alone closely followed by RT alone were the more frequently given treatments, whereas ADT alone and AS were less frequently adopted. This finding is not unexpected as some authors have reported that surgical treatments have long been the most frequently adopted strategy in Italy for PCA \[[@pone.0224151.ref020]\]. These findings are in line with a recent US study, based on the Surveillance, Epidemiology and End Results (SEER) database, showing that radical prostatectomy is the most commonly performed procedure (37% of patients) \[[@pone.0224151.ref021]\]. In the present series, surgery was found to be the preferred treatment for the youngest patients without significant comorbidities. Indeed, patients undergoing surgery alone were younger than those prescribed exclusive RT and ADT alone. Of the 690 patients who underwent radical prostatectomy, 58.8% underwent RARP, 24.1% ORP and 15.7% laparoscopic procedure. The pattern may also be linked to some studies reporting that RARP can reduce post-operative morbidity, hospital re-admissions and total admission time and can thus affect the QoL of these patients \[[@pone.0224151.ref022]--[@pone.0224151.ref024]\]. Coughlin et al \[[@pone.0224151.ref024]\] recently conducted a phase III randomized trial analyzing functional and oncological postoperative outcomes up to 24 months after RARP or ORP. There were no statistically significant differences in sexual functions, urinary distress or clinical outcome, although the former showed a slightly better biochemical relapse free survival. The Authors concluded that both RARP and ORP yielded similar functional outcomes at 24 months, but they advised using caution in interpreting the oncological outcomes \[[@pone.0224151.ref025]\]. Pros-IT CNR data also support this conclusion \[[@pone.0224151.ref026]\].

In our data, 2.4% of patients underwent surgery followed by adjuvant RT, 1.8% surgery, RT and ADT, 3% surgery and ADT, the latter in particular when the patient was characterized by high risk features (T3 and GS \>7).

Studies comparing cost-effectiveness and QOL in patients undergoing surgery *vs* RT *vs* combined modality treatments have produced conflicting findings. While one report published in 2012 favored RT plus ADT for high-risk PCA \[[@pone.0224151.ref027]\], another one published in 2013 supported the use of surgery for intermediate-to-high risk PCA \[[@pone.0224151.ref028]\]. When Dorth et al. conducted a cost effectiveness analysis on intermediate-to-high risk PCA and compared RT plus ADT *vs* surgery using a Markov model, their data showed that the former was characterized by better results in terms of clinical outcome and quality-adjusted life expectancy \[[@pone.0224151.ref029]--[@pone.0224151.ref030]\]. An increase in the fraction of high-risk patients treated with surgery has been reported also by the aalysis of the SEER database for the years 2010--2015; this increase does not seem completely justified by the current guidelines \[[@pone.0224151.ref031]\].

In Italy, an increase in the use of External Beam RT (EBRT) for curative treatment of PCA has been documented in two subsequent patterns of practice studies run under the aegis of Italian Association for Radiotherapy and Clinical Oncology (AIRO) \[[@pone.0224151.ref032]--[@pone.0224151.ref033]\]. In the present study, patients treated with EBRT have been referred to radiation oncologist for the most by urologists. Seventy-five percent underwent IGRT; 33.2% 3D-CRT technique, 41.2% IMRT, 24.4% VMAT, 1.2% SBRT. These results seem to confirm that the new technologies are increasingly being used by Italian Radiation Oncology Centers. In comparison with previous patterns of practice studies supported by AIRO, the percentage of PCA patients treated with new RT technologies has increased considerably over recent years, confirming the conclusion that IGRT can improve RT treatment accuracy \[[@pone.0224151.ref034]\] and may reduce severe acute and late urinary/rectal side effects \[[@pone.0224151.ref035]\]. Furthermore, dose escalation, which IMRT/VMAT techniques have greatly facilitated, has become increasingly commonplace in PCA patients in randomized trials demonstrating improved disease control when increasing RT dose are applied \[[@pone.0224151.ref036]--[@pone.0224151.ref037]\]. More recent randomized trials have reported that moderately hypofractionated regimens are equally effective and less disagreeable to patients compared to standard regimens since they reduce total treatment time. These finding seem to support the use of more sophisticated RT technologies (IMRT/VMAT) and IGRT techniques \[[@pone.0224151.ref038]--[@pone.0224151.ref040]\]. Also, in Italy, an increased use of moderately hypofractionated, IGRT treatments has been observed in recent years ([Table 1](#pone.0224151.t001){ref-type="table"}). Finally, although extreme hypofractionated SBRT has been attracting growing interest, convincing but less robust evidence has not led to a larger use \[[@pone.0224151.ref040]--[@pone.0224151.ref041]\].

10.1371/journal.pone.0224151.t001

###### Evolution of techniques and doses 1985 through 2015, according to different subsequent multicentric databases.

![](pone.0224151.t001){#pone.0224151.t001g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Technique/Dose   Patterns of practice I\                 Patterns of practice II\                  Patterns of practice III\                            Pros- IT CNR\
                   (1985--98)\[[@pone.0224151.ref031]\]\   (1999--2003)\[[@pone.0224151.ref032]\]\   (2004--2011)\                                        (2014--2015)\
                   1759 patients                           3001 patients                             2300 patients[\*](#t001fn001){ref-type="table-fn"}   634 patients[^§^](#t001fn002){ref-type="table-fn"}
  ---------------- --------------------------------------- ----------------------------------------- ---------------------------------------------------- ----------------------------------------------------
  2D, n (%)        1315 (75)                               725 (24)                                  \-                                                   \-

  3D, n (%)        444 (25)                                2269 (75)                                 1905 (83)                                            200 (33)

  IMRT, n (%)      \-                                      7 (1)                                     395 (17)                                             248 (42)

  VMAT, n (%)      \-                                                                                Not evaluated                                        147 (24)

  SBRT, n (%)      \-                                                                                \-                                                   7 (1)

  Dose Gy, n (%)                                                                                                                                          

  \< 70            728 (42)                                218 (7)                                   24 (1)                                               107 (20)

  70--75           1021 (58)                               2531 (84)                                 1255 (70)                                            234 (46)

  ≥ 76             \-                                      252 (9)                                   729 (29)                                             174 (34)

  IGRT             \-                                      \-                                        334 (15)                                             476 (75)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*data presented at Urological study group meeting during AIRO Conference 2019

^§^present paper

In the United States (US) a progressive decline in BT was registered between 2004 and 2014 \[[@pone.0224151.ref021]\]. BT is available in some centers. However, the number of patients participating in the Pros-IT CNR study who were prescribed this therapy was very small (1%) and reflects its scarce diffusion at this moment in Italy. A recently published article, based on data from a large multicenter Italian database, has confirmed the safety and efficacy of prostate BT \[[@pone.0224151.ref042]\]. Despite the many advantages of BT (shorter duration, good results and cost effectiveness), the explanation for its limited diffusion may be found in the scarcity of adequately trained radiation oncologists also due to a relatively long learning curve \[[@pone.0224151.ref043]\].

In the recent years, a concomitant increase in the choice not to give definitive treatment was also noted \[[@pone.0224151.ref021]\]. In the US, very recent data on a population of 164.760 PCA patients from SEER database show an increase from 8.1% to 15.8% in AS as initial management from 2010 through 2015; this management strategy was applied to 42.1% of low risk patients in 2015 \[[@pone.0224151.ref031]\]. In our study, AS was adopted in 6% of the cases: according to the main guidelines \[[@pone.0224151.ref001]--[@pone.0224151.ref005]\], a lower than expected fraction of patients with early stage PCA has been addressed to AS and BT. At the same time, it seems that an excess of advanced stage patients has firstly been surgically treated as well as an excess of radical treatments for low/very low risk patients has therefore been proposed.

Several limitations of our study should be acknowledged: participating centers were involved on a voluntary basis and, therefore, a selection bias cannot be excluded; information on factors that could also influence physicians' or patients' treatment choice, including Magnetic Resonance Imaging, objective assessment of preoperative voiding status, volume of the prostate, patients' access to health care services, and surgeon's experience, were not available in the Pros-IT CNR study.

Concluding, the Pros-IT CNR study can be considered a remarkable forum for Italian urology and oncology specialists to analyze and discuss the latest trends and patterns of care for PCA. Future studies will help to clarify the efficacy of treatment strategies in different risk groups and the baseline criteria to be used to select the most appropriate treatment path for each patient.
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